GENE ONLINE|News &
Opinion
Blog

2021-07-16| ChinaIPO

China’s Brii Bio Raises $319 million in the Hong Kong IPO

by Tyler Chen
Share To

China’s Brii Biosciences has raised $319 million in the initial public offering (IPO) in HKEX. The company announced that the proceeds would be used to support the development of its infectious diseases pipeline, including HBV, HIV, and COVID-19 therapies.

The firm released around 111 million shares on July 13th at HK$22.25 per share, and the cornerstone investors have agreed to acquire 47.52% of them.

“Listing on the Hong Kong Stock Exchange marks an important milestone for our company,” Brii Bio’s CEO Zhi Hong pointed out, “By leveraging our remarkable senior management as well as our experience of conducting multi-regional clinical trials, we will continue to expand our pipeline through our in-house R&D efforts, and in-licenses or collaborations on appropriate drug candidates.”

Brii Bio’s main focus is to deliver innovative solutions to treating infectious diseases and central nervous system (CNS) diseases. Their star pipeline included treatments for HBV, HIV, multidrug-resistant (MDR), extensive drug-resistant (XDR) gram-negative infections, and COVID-19.

Currently, the COVID-19 antibodies BRII-196 and BRII-198 are the most advanced in clinical trials. Both of them have entered phase 3 clinical trials. On the other hand, HBV therapies BRII-179 (immuno-therapy), BRII-835 (siRNA), and the combination therapies come next, entering Phase 2 clinical trials while HIV treatments are in Phase 1 trials.

As for CNS therapies, BRII-296 is tested for two indications: a Phase 1 clinical trial targeting postpartum depression (PPD) and the other in the preclinical stage addressing major depressive disorder (MDD).

On March 23rd, Brii Bio finished the Series C financing, scoring $155 million to boost its current pipeline.

Related Article: Chinese Oncology Drugmaker to Raise over 600 Million in Hong Kong IPO

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Moderna To Collaborate With Harbour BioMed On Nucleic Acid-Based Cancer Therapies
2022-11-14
WuXi Biologics, Toregem BioPharma To Develop Tooth-Regenerating Antibody
2022-10-14
Will Biden’s Biomanufacturing Initiative Kill Korean Partnership?
2022-10-12
LATEST
Repairing Genetic Mutations in Neurological Diseases with RNA Targeting Strategy
2022-11-25
AstraZeneca Thailand Wins Two ACES Awards 2022: “Industry Champions of the Year” and “Community Initiative”
2022-11-24
Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND
2022-11-24
Novartis Shifts Gear To Phase 3 For Anti-Malaria Drug
2022-11-24
Moving Past Animal Models with Better Data for Drug Discovery
2022-11-23
IonOpticks ushers in a new age of proteomics with Aurora Frontier
2022-11-23
Korea Ginseng Corp.: As an adaptogenic herb, Korean red ginseng boosts the human immune response
2022-11-23
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!